Human Siglec-14, a member of the Siglec family of sialic acid-binding lectins, shows extensive sequence similarity to human Siglec-5. To analyze respective expression patterns of Siglec-14 and Siglec-5, we developed specific antibodies against each of them. We found that the former was expressed on granulocytes and monocytes, while the latter was on granulocytes and B-cells. Surprisingly, some individuals lacked the expression of Siglec-14, while they all expressed Siglec-5. We found that a fusion between SIGLEC14 and SIGLEC5 genes, resulting in the functional deletion of SIGLEC14, underlies this phenotype. The presence of the "SIGLEC14 null" allele in all human populations we tested implies an ancient origin, while its allelic frequency is higher in Asians compared with Africans and Europeans. The forced expression of Siglec-14 in a monocytic cell lineenhanced TNF-α secretion elicited by lipopolysaccharide. These results imply that Siglec-14 may play some role in bacterial infection.
Introduction
Siglecs are a family of mammalian lectins that recognize sialic acids Crocker et al. 2007 ). We recently discovered Siglec-14, a Siglec that shows extensive sequence similarity to Siglec-5 in the amino-terminal part ). Siglec-14 has an arginine residue in the transmembrane domain, by which it associates with a signaling adapter molecule DNAX activating protein 12 (DAP12) (Lanier and Bakker 2000) , and hence is expected to function as an activating molecule. This property contrasts with that of Siglec-5, which associates with protein tyrosine phosphatases and is considered to be an inhibitory molecule (Cornish et al. 1998; Avril et al. 2005) . Based on these facts we proposed that Siglec-14 and Siglec-5 might counteract each other to fine-tune the balance between cell activation and dampening. For these two proteins to counteract each other, they would need to be expressed on the same cells. Thus, ascertaining their respective expression patterns is essential in order for us to gain insight into their individual and collective functions. However, the fact that most of the available anti-Siglec-5 antibodies recognized both Siglec-14 and Siglec-5 ) makes it difficult to analyze their respective expression patterns.
To address this problem, we developed specific probes to recognize Siglec-14 and Siglec-5 and analyzed their expression patterns. We found that Siglec-14 was expressed on granulocytes and monocytes, while Siglec-5 was on granulocytes and B-cells. To our surprise, we found that some individuals lack the expression of Siglec-14 altogether, while the expression of Siglec-5 was intact. We discovered that a fusion between SIGLEC14 and SIGLEC5 genes, a common allelic variation of the SIGLEC14-SIGLEC5 locus, underlies this phenotype.
We also demonstrate that the expression of Siglec-14 on a monocytic cell line enhances lipopolysaccharide-elicited tumor necrosis factor α (TNF-α) secretion and that this effect is dependent on the interaction of Siglec-14 with DAP12. Possible implications for the presence of this allele and its distribution in the human population will be discussed. We have previously reported that most of the available antiSiglec-5 antibodies recognize both Siglec-14 and Siglec-5 . We therefore developed specific probes to recognize Siglec-14 (mouse monoclonal antibody) and , and used them to analyze the expression patterns of the two Siglecs on human peripheral blood leukocytes (Figure 1 ). We found that both Siglec-14 and Siglec-5 are expressed on granulocytes. In addition, Siglec-14 was expressed on monocytes, and Siglec-5 was expressed on B-cells.
Results

Expression patterns of
Some individuals lack the expression of Siglec-14 because of a common genetic polymorphism
In our attempts to test the reproducibility of the above findings, we serendipitously found that some individuals lack the expression of Siglec-14, while the expression of Siglec-5 is intact (Figure 2A ). Because all leukocytes were devoid of Siglec-14 in these individuals (not shown), we hypothesized that these individuals genetically lack the gene encoding for Siglec-14. As we have previously reported , SIGLEC14 and SIGLEC5 are located nearby in tandem, and the DNA sequence of the ∼1.5 kb segment of the SIGLEC14 gene, consisting of the 5 untranslated region (∼0.3 kb) and the 5 -end of the coding region (∼1.2 kb), is >99% identical to that of the corresponding region of the SIGLEC5 gene. These facts led us to hypothesize that unequal cross-over at the highly homologous regions of SIGLEC14 and SIGLEC5 resulted in generation of a SIGLEC14/5 fusion gene, which results in the elimination of the genetic segment unique to SIGLEC14 (and thus the elimination of the Siglec-14 protein; Figure 2B ). An alternative assembly of human genome sequence in GenBank implies the presence of such an allele. To test this hypothesis, we designed 2 primer pairs that specifically amplify parts of SIGLEC14 and SIGLEC5, respectively, and performed genomic PCR of individuals with or without Siglec-14 expression. As expected, we detected a SIGLEC14-specific PCR product from the genomic DNA of those who express Siglec-14, while we were unable to detect it from those who do not ( Figure 2D ). Moreover, in the latter individuals, genomic PCR using the primer pair that amplifies the hypothetical SIGLEC14/5 gene yielded a PCR product of the expected size. DNA sequencing of the PCR product confirmed that these individuals do have a SIGLEC14/5 fusion gene. The primer pair 14F + 5R did not give any product in some Siglec-14 positive individuals, who are presumably homozygous for the wild-type allele.
The SIGLEC14/5 fusion allele is widespread in the human population
To analyze the geographical distribution of the SIGLEC14/5 fusion allele, we performed PCR analyses of genomic DNA samples from six populations (i.e., Sub-Saharan Africans, Northern Europeans, Middle Easterners, Indo-Pakistani, Southeast Asians, and Chinese; 9-10 individuals from each group) using the same set of primers. We found that the SIGLEC14/5 fusion allele is present in all populations tested (Table I) . We noted that the frequency of the SIGLEC14/5 fusion allele was higher in Asians, and this skewed distribution was statistically significant (P = 0.0026, chi-square test).
Siglec-14 expression in THP-1 cells enhances TNF-α secretion
To gain insight into the functional outcome of the loss of Siglec-14, we introduced Siglec-14 into the THP-1 cell line and analyzed the cytokine response to lipopolysaccharide (LPS). THP-1 cells express Siglec-5 at a low level while they do not express Siglec-14 (data not shown). Retroviral transduction of Siglec-5 or Siglec-14 cDNA into THP-1 cells results in the surface expression of these proteins ( Figure 3A) . We differentiated THP-1 cells into macrophage-like cells (THP-1 macrophage) and stimulated with LPS. Upon LPS stimulation, THP-1 macrophages expressing Siglec-14 secreted approximately twice as much TNF-α as control or Siglec-5-expressing THP-1 macrophages ( Figure 3B ). Failure of the Siglec-14 R362A mutant, which is unable to interact with the adapter protein DAP12, to enhance TNF-α secretion implies that this effect is dependent on the interaction between Siglec-14 and DAP12. Indeed, introduction of siRNA that targets DAP12 reversed the increase in TNF-α secretion from Siglec-14-expressing THP-1 macrophages to the baseline level ( Figure 3C ). These results imply that the absence of Siglec-14 results in attenuated cytokine response to some Gram-negative bacteria in null individuals.
Discussion
In this paper, we describe the individual expression patterns of Siglec-5 and Siglec-14 for the first time. The results show that the two proteins demonstrate partial overlap in their patterns of expression. Our results are essentially consistent with the previously reported expression pattern of Siglec-5 which used antibodies that simultaneously recognize both Siglec-5 and Siglec-14 (Cornish et al. 1998; Lock et al. 2004; Nguyen et al. 2006) . Our findings also appear to provide a support to the original hypothesis that Siglec-14 and Siglec-5 are coupled, in that the expression patterns of the two proteins at least partially overlap with each other. However, we also observed apparently the unique expression of Siglec-14 on monocytes and Siglec-5 on B lymphocytes. These results may imply that these Siglecs also play unique roles independent of each other. Our discovery of "Siglec-14 null" individuals was thus unexpected. We previously reported concerted evolution of Siglec-5 and Siglec-14 in all primate species we have tested, and we interpreted this fact as a sign of a selective pressure to maintain the functional balance between Siglec-5 and Siglec-14. However, selective pressure against the loss of the SIGLEC14 gene is moderate, judging from the fact that the Siglec-14 null individuals are healthy. The biological meaning of the existence of the Siglec-14 null allele (i.e., SIGLEC14/5 fusion gene) is elusive, but it is tempting to speculate that it protects the carrier against some infectious disease(s), based on the facts that (1) there is an apparent geographical distortion in the M Yamanaka et al. (B) Influence of Siglec-14 expression on TNF-α production. The expression of wild-type or R119A mutant Siglec-14 significantly enhanced TNF-α production, while the expression of R362A mutant failed to show any effect. Siglec-5 expression also showed no effect. * * * P < 0.01 (Student's t-test) . (C) Involvement of DAP12 in Siglec-14-induced enhancement of TNF-α production. A specific siRNA that suppresses DAP12 expression reversed Siglec-14-induced enhancement of TNF-α production to the control level, while it did not influence baseline TNF-α production in cells expressing Siglec-14 R362A mutant or mock-infected cells. Control siRNA did not show any effect. Statistical significance of the difference between means of the amount of TNF-α produced under two different treatments of the same cell type (e.g., DAP12 siRNA versus control siRNA treatment of Siglec-14-expressing THP-1) was tested. * * * P < 0.01 (Student's t-test) . (D) Suppression of DAP12 mRNA by siRNA. RT-PCR and agarose gel electrophoresis were performed as described in Material and methods. distribution of this allele in the human population and that (2) the forced expression of Siglec-14 on THP-1 cells resulted in enhanced TNF-α response, which may lead to exaggerated or prolonged inflammation. Further studies are needed to test this hypothesis.
Biological functions mediated by the interaction of Siglec-14 with endogenous ligand(s), if any, should also be affected by the loss of Siglec-14. Although mutation of the arginine residue essential for sialic acid recognition (R119A) did not show any effect on TNF-α secretion, it should be noted that this experiment was performed in the absence of exogenous or trans-ligands. The presence of Siglec-14 transligand containing sialic acids may further modify the TNF-α secretion.
In summary, we have discovered a deletion polymorphism of SIGLEC14 that may have some consequences on human health. Identification of what aspect of human health is actually affected will be the subject of future studies.
Material and methods
Preparation of a Siglec-14-specific monoclonal antibody
Recombinant human Siglec-14-Fc proteins (containing Ig-like domains 1 through 3 or Ig-like domain 3 only) were prepared as described . BALB/c mice were repeatedly immunized with purified recombinant human Siglec-14-Fc, and their spleens were used for the generation of hybridomas by standard methodologies at Medical and Biological Laboratories (Nagoya, Japan). Hybridoma clones were screened by flow cytometry of COS-7 cells transiently transfected with Siglec-14 or Siglec-5 full-length protein expression construct, and further screened by flow cytometry using the THP-1 cells stably expressing Siglec-5 or Siglec-14 (preparation of which is described below). Clone 40-1, which produces a Siglec-14-specific antibody, was selected. A monoclonal antibody was purified from serum-free culture supernatant of the clone by absorption to Protein G-Sepharose (GE Healthcare, Chalfont St. Giles, UK).
ExTaq DNA polymerase, 0.5 U (Takara); and 1× ExTaq PCR buffer (Takara). Thermal cycling parameters were as follows: 94
• C, 1 min; (94 • C, 1 min; 58 • C, 1 min; 72 • C, 1 min) × 35 cycles; 72
• C, 7 min. The products were analyzed by agarose gel electrophoresis.
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